{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:20:37Z","timestamp":1793172037331,"version":"4.5.0"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Macau Science and Technology Development fund","award":["FDCT 0019\/2024\/RIA1"],"award-info":[{"award-number":["FDCT 0019\/2024\/RIA1"]}]},{"name":"Macau Science and Technology Development fund","award":["FDCT (0135\/2025\/AFJ, 0001\/2024\/RDP, 0001\/2024\/AKP, 0144\/2022\/A3, 0083\/2024\/RIB2, 0004\/2025\/EQP, 0095\/2024\/RIB2)"],"award-info":[{"award-number":["FDCT (0135\/2025\/AFJ, 0001\/2024\/RDP, 0001\/2024\/AKP, 0144\/2022\/A3, 0083\/2024\/RIB2, 0004\/2025\/EQP, 0095\/2024\/RIB2)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01824-4","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:27:51Z","timestamp":1783344471000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antibody-oligonucleotide conjugates: design principles, intracellular delivery, and translational opportunities"],"prefix":"10.1186","volume":"19","author":[{"given":"Yuqian","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daqiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Zhun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"10","key":"1824_CR1","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41577-025-01207-9","volume":"25","author":"AC Chan","year":"2025","unstructured":"Chan AC, Martyn GD, Carter PJ. Fifty years of monoclonals: the past, present and future of antibody therapeutics. Nat Rev Immunol. 2025;25(10):745\u201365.","journal-title":"Nat Rev Immunol"},{"key":"1824_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.pharmthera.2017.03.004","volume":"177","author":"PJ Kennedy","year":"2017","unstructured":"Kennedy PJ, Oliveira C, Granja PL, Sarmento B. Antibodies and associates: Partners in targeted drug delivery. Pharmacol Ther. 2017;177:129\u201345.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"1824_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the biological missile for targeted cancer therapy. Signal Transduct Target therapy. 2022;7(1):93.","journal-title":"Signal Transduct Target therapy"},{"issue":"12","key":"1824_CR4","doi-asserted-by":"publisher","first-page":"104241","DOI":"10.1016\/j.drudis.2024.104241","volume":"29","author":"M Grairi","year":"2024","unstructured":"Grairi M, Le Borgne M. Antibody-drug conjugates: prospects for the next generation. Drug Discovery Today. 2024;29(12):104241.","journal-title":"Drug Discovery Today"},{"issue":"10","key":"1824_CR5","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"CR Thomas","year":"2020","unstructured":"Thomas CR, Robert L, Matthew J. A WJNRDD. Advances in oligonucleotide drug delivery. Nat Rev Drug Discovery. 2020;19(10):673\u201394.","journal-title":"Nat Rev Drug Discovery"},{"issue":"0","key":"1824_CR6","first-page":"300","volume":"341","author":"T Weimin","year":"2021","unstructured":"Weimin T, Yi C, Hee-Seong J, Yu H, Chinmay MJ, Jing L, et al. Preferential siRNA delivery to injured kidneys for combination treatment of acute kidney injury. J controlled release: official J Controlled Release Soc. 2021;341(0):300\u201313.","journal-title":"J controlled release: official J Controlled Release Soc"},{"issue":"4","key":"1824_CR7","first-page":"714","volume":"27","author":"TC Stanley","year":"2018","unstructured":"Stanley TC, Joseph LW, Frank C, Brenda B. F BJCM RNA-Targeted Ther Cell metabolism. 2018;27(4):714\u201339.","journal-title":"F BJCM RNA-Targeted Ther Cell metabolism"},{"issue":"1","key":"1824_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41587-025-02987-0","volume":"44","author":"SJNB Cormac","year":"2026","unstructured":"Cormac SJNB. Now with oligos: antibody-oligonucleotide conjugates are the new drug modality to watch. Nat Biotechnol. 2026;44(1):3\u20135.","journal-title":"Nat Biotechnol"},{"key":"1824_CR9","doi-asserted-by":"publisher","first-page":"107469","DOI":"10.1016\/j.phrs.2024.107469","volume":"209","author":"J Jiao","year":"2024","unstructured":"Jiao J, Qian Y, Lv Y, Wei W, Long Y, Guo X, et al. Overcoming limitations and advancing the therapeutic potential of antibody-oligonucleotide conjugates (AOCs): Current status and future perspectives. Pharmacol Res. 2024;209:107469.","journal-title":"Pharmacol Res"},{"issue":"12","key":"1824_CR10","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1093\/nar\/gkad415","volume":"51","author":"B Malecova","year":"2023","unstructured":"Malecova B, Burke RS, Cochran M, Hood MD, Johns R, Kovach PR, et al. Targeted tissue delivery of RNA therapeutics using antibody-oligonucleotide conjugates (AOCs). Nucleic Acids Res. 2023;51(12):5901\u201310.","journal-title":"Nucleic Acids Res"},{"issue":"17","key":"1824_CR11","doi-asserted-by":"publisher","first-page":"14852","DOI":"10.1021\/acs.jmedchem.4c00802","volume":"67","author":"M Cochran","year":"2024","unstructured":"Cochran M, Arias D, Burke R, Chu D, Erdogan G, Hood M, et al. Structure-Activity Relationship of Antibody-Oligonucleotide Conjugates: Evaluating Bioconjugation Strategies for Antibody-siRNA Conjugates for Drug Development. J Med Chem. 2024;67(17):14852\u201367.","journal-title":"J Med Chem"},{"issue":"6","key":"1824_CR12","doi-asserted-by":"publisher","first-page":"gkaf241","DOI":"10.1093\/nar\/gkaf241","volume":"53","author":"U Etxaniz","year":"2025","unstructured":"Etxaniz U, Marks I, Albin T, Diaz M, Bhardwaj R, Anderson A, et al. AOC 1044 induces exon 44 skipping and restores dystrophin protein in preclinical models of Duchenne muscular dystrophy. Nucleic Acids Res. 2025;53(6):gkaf241.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"1824_CR13","doi-asserted-by":"publisher","first-page":"4739","DOI":"10.1172\/JCI128205","volume":"129","author":"AF Klein","year":"2019","unstructured":"Klein AF, Varela MA, Arandel L, Holland A, Naouar N, Arzumanov A, et al. Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice. J Clin Investig. 2019;129(11):4739\u201344.","journal-title":"J Clin Investig"},{"issue":"1","key":"1824_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12987-025-00643-y","volume":"22","author":"G Bonvicini","year":"2025","unstructured":"Bonvicini G, Singh S, Sandersj\u00f6\u00f6 L, Sehlin D, Syv\u00e4nen S, Andersson KG. The effects of dose, valency, and affinity on TfR-mediated brain delivery in vivo. Fluids barriers CNS. 2025;22(1):36.","journal-title":"Fluids barriers CNS"},{"issue":"6","key":"1824_CR15","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat reviews Clin Oncol. 2021;18(6):327\u201344.","journal-title":"Nat reviews Clin Oncol"},{"key":"1824_CR16","doi-asserted-by":"crossref","unstructured":"Li JH, Liu L, Zhao XH. Precision targeting in oncology: The future of conjugated drugs. Volume 177. Biomedicine & pharmacotherapy\u2009=\u2009Biomedecine & pharmacotherapie; 2024. p. 117106.","DOI":"10.1016\/j.biopha.2024.117106"},{"issue":"0","key":"1824_CR17","first-page":"107292","volume":"215","author":"L Meng","year":"2025","unstructured":"Meng L, Hongxin A, Jialing Z, Weiyu L, Chuanfei Y, Lan WJEJPS. Advances in the pharmaceutical development of antibody-oligonucleotide conjugates. Eur J Pharm Sci. 2025;215(0):107292.","journal-title":"Eur J Pharm Sci"},{"issue":"0","key":"1824_CR18","first-page":"143515","volume":"310","author":"J Naitik","year":"2025","unstructured":"Naitik J, Amrita Arup R, Geethu M, Namitha KP, Rahul P, Muralidhar P, et al. Unlocking the future: Precision oligonucleotide therapy for targeted treatment of neurodegenerative disorders. Int J Biol Macromol. 2025;310(0):143515.","journal-title":"Int J Biol Macromol"},{"issue":"17","key":"1824_CR19","doi-asserted-by":"publisher","first-page":"14868","DOI":"10.1021\/acs.jmedchem.4c00803","volume":"67","author":"M Cochran","year":"2024","unstructured":"Cochran M, Marks I, Albin T, Arias D, Kovach P, Darimont B, et al. Structure-Activity Relationship of Antibody-Oligonucleotide Conjugates: Evaluating Bioconjugation Strategies for Antibody-Phosphorodiamidate Morpholino Oligomer Conjugates for Drug Development. J Med Chem. 2024;67(17):14868\u201384.","journal-title":"J Med Chem"},{"key":"1824_CR20","doi-asserted-by":"publisher","unstructured":"Fan W, Luan W, Yu W, Li Y, Wei C, Liu X, et al. Research progress and development strategies of antibody-oligonucleotide conjugates. Gene Ther. 2026. https:\/\/doi.org\/10.1038\/s41434-026-00621-5.","DOI":"10.1038\/s41434-026-00621-5"},{"issue":"6","key":"1824_CR21","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nbt1101","volume":"23","author":"S Erwei","year":"2005","unstructured":"Erwei S, Pengcheng Z, Sang-Kyung L, Dipanjan C, Steven K, Derek MD, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol. 2005;23(6):709\u201317.","journal-title":"Nat Biotechnol"},{"issue":"0","key":"1824_CR22","first-page":"708806","volume":"12","author":"CU Jeffrey","year":"2021","unstructured":"Jeffrey CU, Steven W, dTJFI. Antibody Conjugates for Targeted Therapy Against HIV-1 as an Emerging Tool for HIV-1 Cure. Front Immunol. 2021;12(0):708806.","journal-title":"Front Immunol"},{"issue":"18","key":"1824_CR23","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.1039\/D2SC01672A","volume":"13","author":"W Xingxing","year":"2022","unstructured":"Xingxing W, Xiao X, Yi F, Jinbo L, Yan ZJCS. A photoresponsive antibody-siRNA conjugate for activatable immunogene therapy of cancer. Chem Sci. 2022;13(18):5345\u201352.","journal-title":"Chem Sci"},{"issue":"4","key":"1824_CR24","doi-asserted-by":"publisher","first-page":"838","DOI":"10.3390\/jcm10040838","volume":"10","author":"D-T Julien","year":"2021","unstructured":"Julien D-T, Srinath T, Nareshkumar JJJCM. Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates. J Clin Med. 2021;10(4):838.","journal-title":"J Clin Med"},{"issue":"1","key":"1824_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12964-025-02605-1","volume":"24","author":"T Yin","year":"2025","unstructured":"Yin T, Yesiltepe M, Metkar S, Ramon A, Greenig M, Sormanni P, et al. The NewroBus platform: engineered humanized anti-TfR1 nanobodies for efficient brain delivery. Cell communication signaling: CCS. 2025;24(1):69.","journal-title":"Cell communication signaling: CCS"},{"issue":"4","key":"1824_CR26","first-page":"546","volume":"33","author":"M-S Viana","year":"2024","unstructured":"Viana M-S, Bryan AMC, Frank CC, Nery AJM, Maria ACV, Rafael MP, et al. Selection of LRP1 ligand phage-displayed single domain antibody that transmigrates BBB. J Drug Target. 2024;33(4):546\u201355.","journal-title":"J Drug Target"},{"issue":"3","key":"1824_CR27","first-page":"338","volume":"51","author":"T Asami","year":"2022","unstructured":"Asami T, Yasuhisa S, Daisuke S, Yoshiyuki K, Junichi EJDMD. Comprehensive analyses of the intracellular and in vivo disposition of fab- small interfering RNA conjugate to identify key issues to improve its in vivo activity. Drug Metab Dispos. 2022;51(3):338\u201347.","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"1824_CR28","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1056\/NEJMoa2407326","volume":"394","author":"EJ Nicholas","year":"2026","unstructured":"Nicholas EJ, Li-Jung T, Johanna IH, John WD, Jeffrey MS, Payam S, et al. An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1. N Engl J Med. 2026;394(8):763\u201372.","journal-title":"N Engl J Med"},{"issue":"1","key":"1824_CR29","doi-asserted-by":"publisher","first-page":"2111748","DOI":"10.1080\/19420862.2022.2111748","volume":"14","author":"RJM Md Harunur","year":"2022","unstructured":"Md Harunur RJM. Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation. MAbs. 2022;14(1):2111748.","journal-title":"MAbs"},{"issue":"3","key":"1824_CR30","doi-asserted-by":"publisher","first-page":"103489","DOI":"10.1016\/j.drudis.2023.103489","volume":"28","author":"P-G Marta","year":"2023","unstructured":"Marta P-G, Ruben A, Arturo L-CJDDT. The myotonic dystrophy type 1 drug development pipeline: 2022 edition. Drug Discovery Today. 2023;28(3):103489.","journal-title":"Drug Discovery Today"},{"issue":"130","key":"1824_CR31","first-page":"130ra148","volume":"4","author":"Y Yan-dan","year":"2012","unstructured":"Yan-dan Y, Tian-meng S, Song-yin H, Shuang D, Ling L, Jia-ning C, et al. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2\u2009+\u2009breast cancer growth and metastasis. Sci Transl Med. 2012;4(130):130ra148.","journal-title":"Sci Transl Med"},{"issue":"3","key":"1824_CR32","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1021\/acs.molpharmaceut.0c01001","volume":"18","author":"Z Oleksandr","year":"2021","unstructured":"Oleksandr Z, Bodo B, Peter C, Luciana Z, Matthias O, Carlo B, et al. Nanobody-siRNA Conjugates for Targeted Delivery of siRNA to Cancer Cells. Mol Pharm. 2021;18(3):1048\u201360.","journal-title":"Mol Pharm"},{"issue":"1","key":"1824_CR33","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/14712598.2024.2436094","volume":"25","author":"U Binder","year":"2025","unstructured":"Binder U, Skerra A. Strategies for extending the half-life of biotherapeutics: successes and complications. Expert Opin Biol Ther. 2025;25(1):93\u2013118.","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"1824_CR34","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","volume":"10","author":"H Mercedes","year":"2024","unstructured":"Mercedes H, Giulia P, Jayesh D, Elena G, Lillian LS, Thiago MS, et al. Bispecific antibodies: advancing precision oncology. Trends cancer. 2024;10(10):893\u2013919.","journal-title":"Trends cancer"},{"issue":"3","key":"1824_CR35","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nbt.3779","volume":"35","author":"TC Stanley","year":"2017","unstructured":"Stanley TC, Shiyu W, Timothy AV, Wen S, Xue-Hai LJNB. Cellular uptake and trafficking of antisense oligonucleotides. Nat Biotechnol. 2017;35(3):230\u20137.","journal-title":"Nat Biotechnol"},{"issue":"0","key":"1824_CR36","first-page":"259","volume":"50","author":"C Frank","year":"2010","unstructured":"Frank C, Eric B. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol. 2010;50(0):259\u201393.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1824_CR37","doi-asserted-by":"publisher","first-page":"104858","DOI":"10.1016\/j.critrevonc.2025.104858","volume":"215","author":"Q Meng","year":"2025","unstructured":"Meng Q, Yang M, Xing F, Xie Z, Hao Y, Jiang P, et al. Antibody-oligonucleotide conjugates in cancer therapy: Potential and Promise. Crit Rev Oncol\/Hematol. 2025;215:104858.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"5","key":"1824_CR38","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.biotechadv.2019.04.012","volume":"37","author":"W Yuhua","year":"2019","unstructured":"Yuhua W, Haihua X, Jinchao Z, Xing-Jie L, Yuanyu HJBA. RNAi therapeutic and its innovative biotechnological evolution. Biotechnol Adv. 2019;37(5):801\u201325.","journal-title":"Biotechnol Adv"},{"issue":"2","key":"1824_CR39","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3390\/bios12020093","volume":"12","author":"F Wang","year":"2022","unstructured":"Wang F, Li P, Chu HC, Lo PK. Nucleic Acids and Their Analogues for Biomedical Applications. Biosens (Basel). 2022;12(2):93.","journal-title":"Biosens (Basel)"},{"issue":"1","key":"1824_CR40","first-page":"69","volume":"1489","author":"A A LJBBA","year":"2000","unstructured":"A A LJBBA. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta. 2000;1489(1):69\u201384.","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"1824_CR41","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1093\/nar\/gkad067","volume":"51","author":"E Martin","year":"2023","unstructured":"Martin E, Muthiah MJNAR. Chemistry, structure and function of approved oligonucleotide therapeutics. Nucleic Acids Res. 2023;51(6):2529\u201373.","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"1824_CR42","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/S1567-5769(02)00142-X","volume":"2","author":"PH Scott","year":"2002","unstructured":"Scott PH, Greg B, Grace Y, Alfred C, Patricia G, Angela M, et al. Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int Immunopharmacol. 2002;2(12):1657\u201366.","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"1824_CR43","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1089\/nat.2014.0506","volume":"24","author":"EJNAT Fritz","year":"2014","unstructured":"Fritz EJNAT. Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic acid Ther. 2014;24(6):374\u201387.","journal-title":"Nucleic acid Ther"},{"issue":"4","key":"1824_CR44","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1021\/jm049167j","volume":"48","author":"RA Charles","year":"2005","unstructured":"Charles RA, Namir S, Russell J, Thazha PP, Nishant N, Andres B, et al. Fully 2\u2019-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J Med Chem. 2005;48(4):901\u20134.","journal-title":"J Med Chem"},{"issue":"1","key":"1824_CR45","first-page":"10","volume":"52","author":"PS Punit","year":"2008","unstructured":"Punit PS, Andrew S, Charles RA, Guillermo V, Sam L, Thazha PP, et al. Short antisense oligonucleotides with novel 2\u2019-4\u2019 conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J Med Chem. 2008;52(1):10\u20133.","journal-title":"J Med Chem"},{"issue":"3","key":"1824_CR46","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ymthe.2017.12.021","volume":"26","author":"JF Donald","year":"2018","unstructured":"Donald JF, Christopher RB, Sarfraz S, Casey T, Mark KS, Kun Q, et al. Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates. Mol therapy: J Am Soc Gene Therapy. 2018;26(3):708\u201317.","journal-title":"Mol therapy: J Am Soc Gene Therapy"},{"issue":"1","key":"1824_CR47","first-page":"117","volume":"1489","author":"M MJBBA","year":"2000","unstructured":"M MJBBA. 2\u2019-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation. Biochim Biophys Acta. 2000;1489(1):117\u201330.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"1824_CR48","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1093\/nar\/gki193","volume":"33","author":"E Joacim","year":"2005","unstructured":"Joacim E, H\u00e5kan T, Karl L, Miriam F, Majken W, Yunhe X, et al. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res. 2005;33(1):439\u201347.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"1824_CR49","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1089\/nat.2013.0436","volume":"23","author":"HH Peter","year":"2013","unstructured":"Peter HH, Victor Y, S\u00f8ren O, Susanne K, Niels FN, Anja MH, et al. Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification pattern. Nucleic acid Ther. 2013;23(5):302\u201310.","journal-title":"Nucleic acid Ther"},{"issue":"6","key":"1824_CR50","first-page":"11","volume":"8","author":"MJCOCB Muthiah","year":"2004","unstructured":"Muthiah MJCOCB. RNA interference and chemically modified small interfering RNAs. N Engl J Med. 2004;8(6):11\u201321.","journal-title":"N Engl J Med"},{"issue":"0","key":"1824_CR51","first-page":"77","volume":"721","author":"BB Jesper","year":"2011","unstructured":"Jesper BB, J\u00f8rgen KJMMB. Chemical modification of small interfering RNA. Methods Mol Biol. 2011;721(0):77\u2013103.","journal-title":"Methods Mol Biol"},{"issue":"14","key":"1824_CR52","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1093\/nar\/gkw236","volume":"44","author":"LJJNAR Rudolph","year":"2016","unstructured":"Rudolph LJJNAR. The delivery of therapeutic oligonucleotides. Nucleic Acids Res. 2016;44(14):6518\u201348.","journal-title":"Nucleic Acids Res"},{"key":"1824_CR53","doi-asserted-by":"crossref","unstructured":"Aimee LJ, Julja B, Devin L, Angela R, Janell S, Jie G et al. Position-specific chemical modification of siRNAs reduces off-target transcript silencing. RNA (New York, NY). 2006; 12(7): 1197\u20131205.","DOI":"10.1261\/rna.30706"},{"issue":"0","key":"1824_CR54","first-page":"117825","volume":"110","author":"L Qiang","year":"2024","unstructured":"Qiang L, Mingxin D, Pu CJBMC. Advances in structural-guided modifications of siRNA. Bioorg Med Chem. 2024;110(0):117825.","journal-title":"Bioorg Med Chem"},{"issue":"5","key":"1824_CR55","first-page":"900","volume":"82","author":"M Wai Kit","year":"2021","unstructured":"Wai Kit M, Dillon MV, Juergen S, Ana SHC, Kuan-Ting L, Hyun Yong J, et al. ASO-Based PKM Splice-Switching Therapy Inhibits Hepatocellular Carcinoma Growth. Cancer Res. 2021;82(5):900\u201315.","journal-title":"Cancer Res"},{"issue":"3","key":"1824_CR56","first-page":"e202415272","volume":"64","author":"Z Liujuan","year":"2024","unstructured":"Liujuan Z, Jie B, Shenghai C, Zhaoshuai B, Junqi Y, Ruru W, et al. Self-Assembled Antibody-Oligonucleotide Conjugates for Targeted Delivery of Complementary Antisense Oligonucleotides. Angew Chem Int Ed Engl. 2024;64(3):e202415272.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"1","key":"1824_CR57","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/17460441.2024.2440095","volume":"20","author":"R Ruchi","year":"2024","unstructured":"Ruchi R, Govind Mukesh R, Vikas K, Raman BJEODD. Evolution of antisense oligonucleotides: navigating nucleic acid chemistry and delivery challenges. Expert Opin Drug Discov. 2024;20(1):63\u201380.","journal-title":"Expert Opin Drug Discov"},{"issue":"0","key":"1824_CR58","first-page":"46","volume":"87","author":"SG Richard","year":"2015","unstructured":"Richard SG, Daniel N, Rosie Y, C Frank BJADDR. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev. 2015;87(0):46\u201351.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"1824_CR59","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1038\/s41467-025-59494-8","volume":"16","author":"S Md Nur Ahad","year":"2025","unstructured":"Md Nur Ahad S, Harry W-C, Farhia H, Brooklynn P, Laura Edellein S, Radha M, et al. DG9 boosts PMO nuclear uptake and exon skipping to restore dystrophic muscle and cardiac function. Nat Commun. 2025;16(1):4477.","journal-title":"Nat Commun"},{"issue":"2","key":"1824_CR60","doi-asserted-by":"publisher","first-page":"295","DOI":"10.4049\/jimmunol.2200950","volume":"211","author":"LM Caitlyn","year":"2023","unstructured":"Caitlyn LM, Idit S-B, Patrick N, Debra KC, Carolyn RB, Jennifer RC, et al. Targeted TLR9 Agonist Elicits Effective Antitumor Immunity against Spontaneously Arising Breast Tumors. J Immunol. 2023;211(2):295\u2013305.","journal-title":"J Immunol"},{"issue":"9","key":"1824_CR61","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/s41416-022-01876-6","volume":"127","author":"D Zhangchi","year":"2022","unstructured":"Zhangchi D, Jian L, Yuzhang WJBJC. Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity. Br J Cancer. 2022;127(9):1584\u201394.","journal-title":"Br J Cancer"},{"issue":"1","key":"1824_CR62","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nprot.2015.137","volume":"11","author":"B Nicole","year":"2015","unstructured":"Nicole B, Neele A, Lisa T, Frank B, Claudia R, Carsten M-T, et al. Antibody-coupled siRNA as an efficient method for in vivo mRNA knockdown. Nat Protoc. 2015;11(1):22\u201336.","journal-title":"Nat Protoc"},{"issue":"10","key":"1824_CR63","doi-asserted-by":"publisher","first-page":"5281","DOI":"10.1093\/nar\/gkaa286","volume":"48","author":"RN Alex","year":"2020","unstructured":"Alex RN, Alexander V, Ki, Christopher T, Justin MP, Zhi Xiang V, Ashish G, et al. Generation and validation of structurally defined antibody-siRNA conjugates. Nucleic Acids Res. 2020;48(10):5281\u201393.","journal-title":"Nucleic Acids Res"},{"issue":"13","key":"1824_CR64","first-page":"e202114016","volume":"61","author":"J Cheng","year":"2021","unstructured":"Cheng J, Afaf HE-S, Siqi L, Katherine AV, Weihong T, Tom BJACIEE. Engineering Enzyme-Cleavable Oligonucleotides by Automated Solid-Phase Incorporation of Cathepsin B Sensitive Dipeptide Linkers. Angew Chem. 2021;61(13):e202114016.","journal-title":"Angew Chem"},{"issue":"2","key":"1824_CR65","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3390\/pharmaceutics14020396","volume":"14","author":"S Rotimi","year":"2022","unstructured":"Rotimi S, Beatriz G, dlT, Fernando AJP. Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate. Pharmaceutics. 2022;14(2):396.","journal-title":"Pharmaceutics"},{"issue":"21","key":"1824_CR66","doi-asserted-by":"publisher","first-page":"12109","DOI":"10.1002\/anie.202103180","volume":"60","author":"J Muhammad","year":"2021","unstructured":"Muhammad J, Jacob R, Heemal HD, Andrei L, Stephen LB, Bradley LPJACIEE. Oligonucleotide Bioconjugation with Bifunctional Palladium Reagents. Angew Chem. 2021;60(21):12109\u201315.","journal-title":"Angew Chem"},{"issue":"3","key":"1824_CR67","first-page":"747","volume":"6","author":"X Chun-Fang","year":"2008","unstructured":"Chun-Fang X, Ruben JB, William MPJMP. Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology. Mol Pharm. 2008;6(3):747\u201351.","journal-title":"Mol Pharm"},{"issue":"3","key":"1824_CR68","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1021\/bc400505q","volume":"25","author":"Z Qun","year":"2014","unstructured":"Qun Z, James ES, Charlene M, Josephine K, Bo C, Diego AG, et al. Site-specific antibody-drug conjugation through glycoengineering. Bioconjug Chem vol. 2014;25(3):510\u201320.","journal-title":"Bioconjug Chem vol"},{"issue":"10","key":"1824_CR69","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1073\/pnas.1120682109","volume":"109","author":"AK Stephanie","year":"2012","unstructured":"Stephanie AK, Devin S, Edward HC, Maria Loressa U, Peter K, Peter GS, et al. Site-specific DNA-antibody conjugates for specific and sensitive immuno-PCR. Proc Natl Acad Sci USA. 2012;109(10):3731\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"1824_CR70","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"B Alain","year":"2017","unstructured":"Alain B, Liliane G, Charles D, Nathalie CJNRDD. Strategies and challenges for the next generation of antibody-drug conjugates. Drug discovery. 2017;16(5):315\u201337.","journal-title":"Drug discovery"},{"issue":"5","key":"1824_CR71","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1080\/19420862.2019.1602459","volume":"11","author":"KC Dilip","year":"2019","unstructured":"Dilip KC, Xiaoli W, H\u00e9ctor P\u00e9rez M, Ramraj V, Raimund JO, Sally E. Neonatal Fc receptor expression in macrophages is indispensable for IgG homeostasis. mAbs. 2019;11(5):848\u201360.","journal-title":"mAbs"},{"issue":"10","key":"1824_CR72","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.1093\/nar\/gkaa299","volume":"48","author":"TC Stanley","year":"2020","unstructured":"Stanley TC, Timothy AV, Xue-Hai LJNAR. Phosphorothioate modified oligonucleotide-protein interactions. Nucleic Acids Res. 2020;48(10):5235\u201353.","journal-title":"Nucleic Acids Res"},{"issue":"18","key":"1824_CR73","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.3390\/cells12182253","volume":"12","author":"M Priyanka","year":"2023","unstructured":"Priyanka M, Quentin V, Annabelle BJC. Therapeutic Oligonucleotides: An Outlook on Chemical Strategies to Improve Endosomal Trafficking. Cells. 2023;12(18):2253.","journal-title":"Cells"},{"issue":"3","key":"1824_CR74","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nbt.3765","volume":"35","author":"K Anastasia","year":"2017","unstructured":"Anastasia K, Jonathan KWJNB. The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol. 2017;35(3):238\u201348.","journal-title":"Nat Biotechnol"},{"key":"1824_CR75","first-page":"35","volume":"870","author":"K CJADDR","year":"2015","unstructured":"R L J, K CJADDR. Cellular uptake and intracellular trafficking of oligonucleotides. Adv Drug Deliv Rev. 2015;870:35\u201345.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"1824_CR76","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10928-011-9232-2","volume":"39","author":"KS Dhaval","year":"2011","unstructured":"Dhaval KS, Alison MBJJPP. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. 2011;39(1):67\u201386.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"1824_CR77","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s43856-025-00733-w","volume":"5","author":"W Timothy","year":"2025","unstructured":"Timothy W, Tyler P, Brendan Q, Sean S, Pei-Yi S, Qifeng Q, et al. FORCE platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy features in preclinical models. Commun Med. 2025;5(1):22.","journal-title":"Commun Med"},{"issue":"1","key":"1824_CR78","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41416-020-01179-8","volume":"124","author":"K Imran","year":"2020","unstructured":"Imran K, Patricia SSJBJC. Endocytosis: a pivotal pathway for regulating metastasis. Br J Cancer. 2020;124(1):66\u201375.","journal-title":"Br J Cancer"},{"key":"1824_CR79","doi-asserted-by":"crossref","unstructured":"Chong Q, Fei X, Junzhe Z, Qiaoli S, Yuqing M, Chen W et al. Advanced Strategies for Overcoming Endosomal\/Lysosomal Barrier in Nanodrug Delivery. Research (Washington, DC). 2023; 6(0): 0148.","DOI":"10.34133\/research.0148"},{"issue":"1","key":"1824_CR80","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1038\/s41467-024-46321-9","volume":"15","author":"F Stian","year":"2024","unstructured":"Stian F, Siri AS, Leire A, Marta L, Jutamas S, Ana Rita C, et al. Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria. Nat Commun. 2024;15(1):2007.","journal-title":"Nat Commun"},{"issue":"1","key":"1824_CR81","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41392-024-02112-8","volume":"10","author":"L Mohan","year":"2025","unstructured":"Mohan L, Yusi W, Yibing Z, Die H, Lin T, Bailing Z, et al. Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines. Signal Transduct Target therapy. 2025;10(1):73.","journal-title":"Signal Transduct Target therapy"},{"issue":"4","key":"1824_CR82","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s40259-024-00665-2","volume":"38","author":"A Sang","year":"2024","unstructured":"Sang A, Zhuo S, Bochanis A, Manautou JE, Bahal R, Zhong XB, et al. Mechanisms of action of the US food and drug administration-approved antisense oligonucleotide drugs. BioDrugs. 2024;38(4):511\u201326.","journal-title":"BioDrugs"},{"key":"1824_CR83","doi-asserted-by":"publisher","first-page":"750","DOI":"10.3389\/fmicb.2018.00750","volume":"9","author":"Y Nan","year":"2018","unstructured":"Nan Y, Zhang YJ. Antisense Phosphorodiamidate Morpholino Oligomers as Novel Antiviral Compounds. Front Microbiol. 2018;9:750.","journal-title":"Front Microbiol"},{"issue":"5","key":"1824_CR84","first-page":"497","volume":"14","author":"R Maria Abdul Ghafoor","year":"2020","unstructured":"Maria Abdul Ghafoor R, Haliza K, Muhammad Wahab AJAJPS. Design, mechanism, delivery and therapeutics of canonical and Dicer-substrate siRNA. Asian J Pharm Sci. 2020;14(5):497\u2013510.","journal-title":"Asian J Pharm Sci"},{"issue":"7","key":"1824_CR85","doi-asserted-by":"publisher","first-page":"6870","DOI":"10.1021\/acs.jmedchem.4c02528","volume":"68","author":"A Puneet","year":"2025","unstructured":"Puneet A, Yu Z, Spoorthi P, Keerat KJJMC. Metabolic Stability and Targeted Delivery of Oligonucleotides: Advancing RNA Therapeutics Beyond The Liver. J Med Chem. 2025;68(7):6870\u201396.","journal-title":"J Med Chem"},{"issue":"1","key":"1824_CR86","doi-asserted-by":"publisher","first-page":"5881","DOI":"10.1038\/s41598-021-85352-w","volume":"11","author":"L Victor","year":"2021","unstructured":"Victor L, Isabelle K, Marc N, St\u00e9phane E, Sergii K, Sarah C, et al. Non-specific interactions of antibody-oligonucleotide conjugates with living cells. Sci Rep. 2021;11(1):5881.","journal-title":"Sci Rep"},{"issue":"1","key":"1824_CR87","first-page":"6","volume":"21","author":"MJNRDD Asher","year":"2021","unstructured":"Asher MJNRDD. Antibody-oligonucleotide conjugates enter the clinic. Nat Rev Drug Discovery. 2021;21(1):6\u20138.","journal-title":"Nat Rev Drug Discovery"},{"issue":"20","key":"1824_CR88","doi-asserted-by":"publisher","first-page":"11401","DOI":"10.1093\/nar\/gkac641","volume":"50","author":"AD Cody","year":"2022","unstructured":"Cody AD, Monica Y, John H, Emma OD, Reshmii V, Sean S, et al. Enhanced exon skipping and prolonged dystrophin restoration achieved by TfR1-targeted delivery of antisense oligonucleotide using FORCE conjugation in mdx mice. Nucleic Acids Res. 2022;50(20):11401\u201314.","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"1824_CR89","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1038\/mt.2008.120","volume":"16","author":"J Natee","year":"2008","unstructured":"Natee J, Hong MM, Brian B, Jennifer R, Peter S, Suthat F, et al. Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther. 2008;16(9):1624\u20139.","journal-title":"Mol Ther"},{"issue":"16","key":"1824_CR90","doi-asserted-by":"publisher","first-page":"9065","DOI":"10.3390\/ijms25169065","volume":"25","author":"LB Samuel","year":"2024","unstructured":"Samuel LB, Toshifumi YJIJMS. Oligonucleotide Therapies for Facioscapulohumeral Muscular Dystrophy: Current Preclinical Landscape. Int J Mol Sci. 2024;25(16):9065.","journal-title":"Int J Mol Sci"},{"key":"1824_CR91","doi-asserted-by":"publisher","first-page":"632","DOI":"10.2119\/molmed.2015.00210","volume":"22","author":"S Noriko","year":"2016","unstructured":"Noriko S, Connie D, Sakiko Y, Michael O, Cathy C, Rachael P, et al. Novel targeted therapy for precursor B cell acute lymphoblastic leukemia: anti-CD22 antibody-MXD3 antisense oligonucleotide conjugate. Mol Med. 2016;22:632\u201342.","journal-title":"Mol Med"},{"issue":"10","key":"1824_CR92","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1073\/pnas.0608491104","volume":"104","author":"P Dan","year":"2007","unstructured":"Dan P, Pengcheng Z, Christopher VC, Judy L, Motomu SJPNASUSA. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci U S A. 2007;104(10):4095\u2013100.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"0","key":"1824_CR93","first-page":"153303382110414","volume":"20","author":"KSRSKH Lakshmi","year":"2021","unstructured":"Lakshmi KSRSKH, Reena S. Cetuximab-siRNA Conjugate Linked Through Cationized Gelatin Knocks Down KRAS G12C Mutation in NSCLC Sensitizing the Cells Toward Gefitinib. Technol Cancer Res Treat. 2021;20(0):15330338211041453.","journal-title":"Technol Cancer Res Treat"},{"issue":"0","key":"1824_CR94","first-page":"518","volume":"11","author":"EA Amy","year":"2018","unstructured":"Amy EA, Elise M-A, Phuong UL, Anika M, Sa\u00fal M-M, Kevin P, et al. Antibody-Antisense Oligonucleotide Conjugate Downregulates a Key Gene in Glioblastoma Stem Cells. Nucleic Acids Res. 2018;11(0):518\u201327.","journal-title":"Nucleic Acids Res"},{"issue":"23","key":"1824_CR95","doi-asserted-by":"publisher","first-page":"5948","DOI":"10.1158\/1078-0432.CCR-18-1277","volume":"24","author":"M Dayson","year":"2018","unstructured":"Dayson M, Tomasz A, Xingli Z, Yu-Lin S, Zhuoran Z, Seok Voon W, et al. STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers. Clin cancer research: official J Am Association Cancer Res. 2018;24(23):5948\u201362.","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"issue":"9","key":"1824_CR96","first-page":"e194","volume":"3","author":"M Gabriella","year":"2014","unstructured":"Gabriella M, Maria Teresa DM, Giuseppe DR, Ammad Ahmad F, Angela L, Virginia C, et al. Mir-34: a new weapon against cancer? Mol therapy Nucleic acids. 2014;3(9):e194.","journal-title":"Mol therapy Nucleic acids"},{"issue":"36","key":"1824_CR97","first-page":"e04468","volume":"21","author":"R Youngri","year":"2025","unstructured":"Youngri R, Eun Hye K, Hochung J, Yelee K, Byeongmin P, Jiwoong C, et al. Targeted Delivery of miR-34a via Anti-CD47 Antibody Conjugates for Enhanced Cancer Immunotherapy in Triple Negative Breast Cancer. Small (Weinheim an der Bergstrasse. Germany). 2025;21(36):e04468.","journal-title":"Germany)"},{"issue":"3","key":"1824_CR98","doi-asserted-by":"publisher","first-page":"e970918","DOI":"10.4161\/21624011.2014.970918","volume":"4","author":"B S","year":"2015","unstructured":"S B, B A, B R, W A, L A, GJO E. Reducing toxicity of 4-1BB costimulation: targeting 4-1BB ligands to the tumor stroma with bi-specific aptamer conjugates. Oncoimmunology. 2015;4(3):e970918.","journal-title":"Oncoimmunology"},{"issue":"10","key":"1824_CR99","doi-asserted-by":"publisher","first-page":"Na763","DOI":"10.1038\/nnano.2013.190","volume":"8","author":"J Justin","year":"2013","unstructured":"Justin J, Carlos M, Michael HV, Freddy RM, Emily EE, David C. Self-assembly of carbon nanotubes and antibodies on tumours for targeted amplified delivery. Nat Nanotechnol. 2013;8(10):Na763\u2013771.","journal-title":"Nat Nanotechnol"},{"issue":"6","key":"1824_CR100","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1021\/ja210894g","volume":"134","author":"G Amit","year":"2012","unstructured":"Amit G, Adrian F, Sidath CK, Carston RWJJACS. Programmable self-assembly of antibody-oligonucleotide conjugates as small molecule and protein carriers. J Am Chem Soc. 2012;134(6):2895\u20137.","journal-title":"J Am Chem Soc"},{"issue":"6","key":"1824_CR101","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3390\/cancers17060958","volume":"17","author":"B Idil","year":"2025","unstructured":"Idil B, Ates Kutay T, Ibrahim Halil SJC. Opportunities and Challenges in Antibody-Drug Conjugates for Cancer Therapy: A New Era for Cancer Treatment. Cancers. 2025;17(6):958.","journal-title":"Cancers"},{"issue":"0","key":"1824_CR102","first-page":"59","volume":"8","author":"H Yue","year":"2025","unstructured":"Yue H, Zhengbo SJCDR. Mechanisms of resistance to antibody-drug conjugates in cancer therapy: molecular basis and therapeutic strategies. Cancer drug Resist (Alhambra Calif). 2025;8(0):59.","journal-title":"Cancer drug Resist (Alhambra Calif)"},{"issue":"6","key":"1824_CR103","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s40291-024-00734-w","volume":"28","author":"G Yuheng","year":"2024","unstructured":"Yuheng G, Qi ZJMDT. Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors. Mol Diagn Ther. 2024;28(6):669\u2013702.","journal-title":"Mol Diagn Ther"},{"issue":"0","key":"1824_CR104","first-page":"105003","volume":"216","author":"F Amir Saamaan","year":"2025","unstructured":"Amir Saamaan F, Elahe HJCROH. Beyond monospecificity: The modular revolution of bispecific immunotherapeutics. Crit Rev Oncol\/Hematol. 2025;216(0):105003.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"8","key":"1824_CR105","doi-asserted-by":"publisher","first-page":"e2101262","DOI":"10.1002\/adbi.202101262","volume":"6","author":"R Ping","year":"2022","unstructured":"Ping R, Chuyue Z, Wenping L, Xian W, Aibing L, Guang Y, et al. CAR-T Therapy in Clinical Practice: Technical Advances and Current Challenges. Adv biology. 2022;6(8):e2101262.","journal-title":"Adv biology"},{"issue":"6753","key":"1824_CR106","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"LH Theresa","year":"2025","unstructured":"Theresa LH, Yanjie B, Yan Z, Daiki M, Romina R, Annabel W, et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science. 2025;388(6753):1311\u20137.","journal-title":"Science"},{"issue":"8","key":"1824_CR107","doi-asserted-by":"publisher","first-page":"4474","DOI":"10.1021\/acs.molpharmaceut.5c00385","volume":"22","author":"B Ying","year":"2025","unstructured":"Ying B, Li C, Tianshu L, Zhen W, Haiyan C, Shukun H, et al. Recent Advances in mRNA-LNP Delivery Systems for Extrahepatic Organs: A Review. Mol Pharm. 2025;22(8):4474\u201393.","journal-title":"Mol Pharm"},{"issue":"0","key":"1824_CR108","first-page":"1810121","volume":"17","author":"L Tao","year":"2026","unstructured":"Tao L, Xiaoyan S, Tianhong Z, Weiping GJFP. Key immune checkpoint inhibitor-associated toxicities: from molecular mechanisms to clinical management. Front Pharmacol. 2026;17(0):1810121.","journal-title":"Front Pharmacol"},{"issue":"9","key":"1824_CR109","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1021\/acschembio.5c00318","volume":"20","author":"Y Sayumi","year":"2025","unstructured":"Sayumi Y, Keerthi S, Qian Z, Arvind R, Tim S, Pavel S, et al. Design and Characterization of an Anti-Clec9a Antibody Armed with CpG Oligonucleotides To Enable Targeted Delivery of Adjuvant to Cross-Presenting Dendritic Cells. ACS Chem Biol. 2025;20(9):2180\u201390.","journal-title":"ACS Chem Biol"},{"issue":"24","key":"1824_CR110","doi-asserted-by":"publisher","first-page":"e154142","DOI":"10.1172\/jci.insight.154142","volume":"7","author":"MH Suzan","year":"2022","unstructured":"Suzan MH, Frank A, Larissa G, Jessica S, Matthew B, George T, et al. Antibody-oligonucleotide conjugate achieves CNS delivery in animal models for spinal muscular atrophy. JCI insight. 2022;7(24):e154142.","journal-title":"JCI insight"},{"issue":"84","key":"1824_CR111","first-page":"84ra44","volume":"3","author":"Y Joy","year":"2011","unstructured":"Joy Y, Yin Y, Margaret Z, Kwame K, Wilman H, Yanmei L. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med. 2011;3(84):84ra44.","journal-title":"Sci Transl Med"},{"issue":"7","key":"1824_CR112","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1021\/acs.bioconjchem.5c00225","volume":"36","author":"F Tiancheng","year":"2025","unstructured":"Tiancheng F, Fushun F, Yingying L, Zhenxian M, Minhua Z, Xiaolan Y, et al. TfR1-Binding Peptide Conjugation Facilitates Robust and Specific siRNA Delivery to the Central Nervous System. Bioconjug Chem. 2025;36(7):1377\u201383.","journal-title":"Bioconjug Chem"},{"issue":"Pt 2","key":"1824_CR113","first-page":"114344","volume":"388","author":"D Marion","year":"2025","unstructured":"Marion D, Romy C, Diane B, G\u00e9raldine F, Marina C, Aude F, et al. Novel single-domain antibodies targeting a unique transferrin receptor 1 epitope for cross-species delivery of drugs in the central nervous system. J controlled release: official J Controlled Release Soc. 2025;388(Pt 2):114344.","journal-title":"J controlled release: official J Controlled Release Soc"},{"issue":"20","key":"1824_CR114","doi-asserted-by":"publisher","first-page":"gkaf487","DOI":"10.1093\/nar\/gkaf487","volume":"53","author":"HE Hsia","year":"2025","unstructured":"Hsia HE, Zanini C, Simonneau C, Fraidling J, Kraft TE, Mayer K, et al. Improved targeted delivery of antisense oligonucleotide with an antibody mask. Nucleic Acids Res. 2025;53(20):gkaf487.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1824_CR115","doi-asserted-by":"publisher","first-page":"2592422","DOI":"10.1080\/19420862.2025.2592422","volume":"17","author":"BA Smith","year":"2025","unstructured":"Smith BA, Meeks CB, Murray-Brown I, McCarthy EA, Julian MC, Arndt J, et al. Balancing brain exposure, pharmacokinetics and safety of transferrin receptor antibodies for delivery of neuro-therapeutics. MAbs. 2025;17(1):2592422.","journal-title":"MAbs"},{"issue":"3","key":"1824_CR116","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1067\/mai.2002.122156","volume":"109","author":"VS Joanna","year":"2002","unstructured":"Joanna VS, Gary VN, Paula T, Elizabeth L, Marsha W-KJJACI. Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J Allergy Clin Immunol. 2002;109(3):455\u201362.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1824_CR117","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1067\/mai.2002.126660","volume":"110","author":"AH Anthony","year":"2002","unstructured":"Anthony AH, Kenji T, Lucinda B, Bhavya S, Jose Z, Stephen B, et al. Optimized conjugation ratios lead to allergen immunostimulatory oligodeoxynucleotide conjugates with retained immunogenicity and minimal anaphylactogenicity. J Allergy Clin Immunol. 2002;110(3):413\u201320.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"1824_CR118","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1182\/blood-2008-05-157396","volume":"112","author":"D Chuanlin","year":"2008","unstructured":"Chuanlin D, Li W, Jose M, Jun YJB. Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1. Blood. 2008;112(7):2817\u201325.","journal-title":"Blood"},{"issue":"3","key":"1824_CR119","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.ymthe.2024.01.028","volume":"32","author":"C Shirley Pei Shan","year":"2024","unstructured":"Shirley Pei Shan C, Jeremy Kah Sheng P, Boon-Seng SJMT. Current RNA strategies in treating cardiovascular diseases. Mol therapy: J Am Soc Gene Therapy. 2024;32(3):580\u2013608.","journal-title":"Mol therapy: J Am Soc Gene Therapy"},{"issue":"Suppl1","key":"1824_CR120","first-page":"A4143917","volume":"150","author":"MA Missinato","year":"2024","unstructured":"Missinato MA, Lemoine K, Ho G, Fong J, Wang J, Abdulkadir S, et al. Abstract 4143917: novel precision cardiology treatment for PRKAG2 cardiomyopathy, a subset of patients with wolff-parkinson-white syndrome. Circulation. 2024;150(Suppl1):A4143917.","journal-title":"Circulation"},{"issue":"5","key":"1824_CR121","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.7150\/thno.29884","volume":"9","author":"S Sheng-Jia","year":"2019","unstructured":"Sheng-Jia S, Li-Juan W, Dong-Hui H, Jie-Heng W, Dian J, Kai-Liang Z, et al. Therapeutic effects of human monoclonal PSMA antibody-mediated TRIM24 siRNA delivery in PSMA-positive castration-resistant prostate cancer. Theranostics. 2019;9(5):1247\u201363.","journal-title":"Theranostics"},{"issue":"0","key":"1824_CR122","first-page":"120940","volume":"606","author":"Y Zhili","year":"2021","unstructured":"Zhili Y, Xiaojuan Z, Xing P, Weiran C, Junxiao Y, Jianxin W, et al. Antibody-siRNA conjugates (ARCs) using multifunctional peptide as a tumor enzyme cleavable linker mediated effective intracellular delivery of siRNA. Int J Pharm. 2021;606(0):120940.","journal-title":"Int J Pharm"},{"issue":"6","key":"1824_CR123","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3390\/pharmaceutics12060545","volume":"12","author":"A Yamayoshi","year":"2020","unstructured":"Yamayoshi A, Oyama S, Kishimoto Y, Konishi R, Yamamoto T, Kobori A, et al. Development of Antibody-Oligonucleotide Complexes for Targeting Exosomal MicroRNA. Pharmaceutics. 2020;12(6):545.","journal-title":"Pharmaceutics"},{"issue":"5","key":"1824_CR124","first-page":"1388","volume":"12","author":"L Xiaoyu","year":"2024","unstructured":"Xiaoyu L, Huanhuan H, Hailong W, Jia L, Wenting J, Feng Z, et al. DNA nanotechnology-based strategies for minimising hybridisation-dependent off-target effects in oligonucleotide therapies. Mater Horiz. 2024;12(5):1388\u2013412.","journal-title":"Mater Horiz"},{"issue":"6","key":"1824_CR125","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1089\/nat.2011.0323","volume":"21","author":"F Alexandra","year":"2011","unstructured":"Alexandra F, Ulrike S, Kirsten V, Hans-Peter H, Bernhard N, Sybille T, et al. Dual or triple activation of TLR7, TLR8, and\/or TLR9 by single-stranded oligoribonucleotides. Nucleic acid Ther. 2011;21(6):423\u201336.","journal-title":"Nucleic acid Ther"},{"key":"1824_CR126","doi-asserted-by":"crossref","unstructured":"Steven FDJR. Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem? RNA (New York, NY). 2023;29(4):396\u2013401.","DOI":"10.1261\/rna.079507.122"},{"issue":"7","key":"1824_CR127","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nbt.2612","volume":"31","author":"G Jerome","year":"2013","unstructured":"Jerome G, William Q, Anja Z, Anna B, Giovanni M, Undine S, et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol. 2013;31(7):638\u201346.","journal-title":"Nat Biotechnol"},{"issue":"5","key":"1824_CR128","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1089\/nat.2022.0004","volume":"32","author":"FD Steven","year":"2022","unstructured":"Steven FD, Ryan LS, Xian-Shu C, Satish GJJNAT. Delivery of RNA therapeutics: the great endosomal escape! Nucleic acid Ther. 2022;32(5):361\u201368.","journal-title":"Nucleic acid Ther"},{"issue":"9","key":"1824_CR129","doi-asserted-by":"publisher","first-page":"e202300077","DOI":"10.1002\/cbic.202300077","volume":"24","author":"S Lin","year":"2023","unstructured":"Lin S, Yuanyuan W, Wenxue X, Guangyao C, Hang XJC. Chemical Biology Approaches toward Precise Structure Control of IgG-Based Antibody-Oligonucleotide Conjugates. Chembiochem: Eur J Chem biology. 2023;24(9):e202300077.","journal-title":"Chembiochem: Eur J Chem biology"},{"issue":"8","key":"1824_CR130","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1080\/00498254.2024.2339983","volume":"54","author":"M Anthony","year":"2024","unstructured":"Anthony M, Ryan H, Michael BJX. Bioanalytical approaches to support the development of antibody-oligonucleotide conjugate (AOC) therapeutic proteins. Xenobiotica. 2024;54(8):552\u201362.","journal-title":"Xenobiotica"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01824-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01824-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01824-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:04:53Z","timestamp":1788278693000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01824-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":130,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1824"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01824-4","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"20 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"71"}}